Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
|
|
Cara Therapeutics, Inc. (CARA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Investor presentation |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
4
| Posner Christopher (President and CEO) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 4,307 shares
@ $3.07, valued at
$13.2k
|
|
| 08/04/2023 |
4
| Boudreau Helen M (Director) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Granted 155,747 options to buy
@ $3.09, valued at
$481.3k
|
|
| 08/04/2023 |
3
| Boudreau Helen M (Director) has filed a Form 3 on Cara Therapeutics, Inc. |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/25/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/25/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 6.9% stake in CARA THERAPEUTICS INC |
| 05/09/2023 |
4
| Posner Christopher (President and CEO) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 3,869 shares
@ $4.4, valued at
$17k
|
|
| 04/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
8-K
| Investor presentation |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
4
| Posner Christopher (President and CEO) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 5,987 shares
@ $9.71, valued at
$58.1k
|
|
| 03/07/2023 |
4
| Menzaghi Frederique Ph.D. (Chief Scientific Off,SVP-R&D) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 6,802 shares
@ $9.71, valued at
$66k
|
|
| 03/07/2023 |
4
| Terrillion Scott (Sec'y; Chief Compliance & G.C.) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 6,256 shares
@ $9.71, valued at
$60.7k
|
|
| 03/07/2023 |
4
| Goncalves Joana (Chief Medical Officer) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 6,221 shares
@ $9.71, valued at
$60.4k
|
|
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
4
| Posner Christopher (President and CEO) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 4,191 shares
@ $11.8, valued at
$49.5k
|
|
| 01/20/2023 |
SC 13G/A
| BlackRock Inc. reports a 14.4% stake in CARA THERAPEUTICS INC |
| 01/19/2023 |
4
| von Moltke Lisa (Director) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Granted 45,841 options to buy
@ $10.74, valued at
$492.3k
|
|
| 01/19/2023 |
4
| Goncalves Joana (Chief Medical Officer) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 2,265 shares
@ $10.81, valued at
$24.5k
|
|
| 01/09/2023 |
8-K
| Investor presentation |
| 01/03/2023 |
4
| Goncalves Joana (Chief Medical Officer) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 2,265 shares
@ $10.18, valued at
$23.1k
|
|
| 12/23/2022 |
4
| Menzaghi Frederique Ph.D. (Chief Scientific Off,SVP-R&D) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 3,506 shares
@ $11.27, valued at
$39.5k
|
|
| 12/23/2022 |
4
| Goncalves Joana (Chief Medical Officer) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 2,992 shares
@ $11.27, valued at
$33.7k
|
|
| 12/23/2022 |
4
| Terrillion Scott (Sec'y; Chief Compliance & G.C.) has filed a Form 4 on Cara Therapeutics, Inc.|
Txns:
| Sold 2,561 shares
@ $11.27, valued at
$28.9k
|
|
| 11/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/18/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|
|